JPRN-UMIN000011992已完成未知
Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failure - Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failure
ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya0 个研究点目标入组 40 人开始时间: 2013年10月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •CKD patients with corrected calcium (cCa)<8.5 mg/dl or serum PTH> 110 pg/ml. Patients with dialysis whose serum Ca, P, and PTH are out of the range recommended by JSDT 2012 (cCa 8.5-10.0 mg/dl, P 3.5-6.0 mg/dl, and PTH 60-240 pg/ml)
研究者
相似试验
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000027425Kyoto Prefectural Universuty of Medicine100
已完成
不适用
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
尚未招募
2 期
se of Injection Denosumab in the treatment of Giant Cell Tumour.CTRI/2024/02/062905Dr Sanyam Rathi
进行中（未招募）
1 期
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869